aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-16 16:29Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, following the announcement of disappointing clinical trial results [1][3]. Group 1: Legal Action - The Portnoy Law Firm is advising aTyr Pharma investors regarding a class action lawsuit for those who bought securities between January 16, 2025, and September 12, 2025 [1]. - Investors have until December 8, 2025, to file a lead plaintiff motion in the class action [1]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced topline results from the Phase 3 EFZO-FIT™ study involving 268 patients with pulmonary sarcoidosis, which failed to meet its primary endpoint [3]. - Following the announcement of the trial results, aTyr's stock price experienced a significant decline during intraday trading on the same day [3]. Group 3: Investor Support - The Portnoy Law Firm offers complimentary case evaluations for investors to discuss their legal rights and options for recovering losses [2]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].